Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

CME

Acute Exacerbation of COPD

28 May 2020

initiation of pulmonary rehabilitation within 3 months of hospital discharge after acute COPD exacerbation may reduce 1-year all-cause mortality in older adults (JAMA 2020 May 12)

28 May 2020

initiation of pulmonary rehabilitation within 3 months of hospital discharge after acute COPD exacerbation may reduce 1-year all-cause mortality in older adults (JAMA 2020 May 12)

9 Mar 2020

systemic antibiotics may improve exacerbation resolution at end of treatment in non-ICU inpatients with moderate-to-severe exacerbation of COPD (Ann Intern Med 2020 Feb 25 early online)

9 Mar 2020

systemic antibiotics may improve exacerbation resolution at end of treatment in non-ICU inpatients with moderate-to-severe exacerbation of COPD (Ann Intern Med 2020 Feb 25 early online)

9 Mar 2020

systemic antibiotics may improve exacerbation resolution in adults with mild-to-moderate exacerbation of COPD (Ann Intern Med 2020 Feb 25 early online)

9 Mar 2020

systemic antibiotics may improve exacerbation resolution in adults with mild-to-moderate exacerbation of COPD (Ann Intern Med 2020 Feb 25 early online)

27 Nov 2019

metoprolol increases rate of severe exacerbation in patients with COPD with moderate or severe airflow limitation with increased risk for exacerbation (N Engl J Med 2019 Oct 20 early online)

27 Nov 2019

metoprolol increases rate of severe exacerbation in patients with COPD with moderate or severe airflow limitation with increased risk for exacerbation (N Engl J Med 2019 Oct 20 early online)

27 Nov 2019

metoprolol increases rate of severe exacerbation in patients with COPD with moderate or severe airflow limitation with increased risk for exacerbation (N Engl J Med 2019 Oct 20 early online)

27 Nov 2019

metoprolol increases rate of severe exacerbation in patients with COPD with moderate or severe airflow limitation with increased risk for exacerbation (N Engl J Med 2019 Oct 20 early online)

22 Oct 2019

3-month hospital-initiated program to support patients and family caregivers with long-term self-management of COPD may increase acute care events compared to usual 30-day transitional care (JAMA 2019 Oct 8)

22 Oct 2019

3-month hospital-initiated program to support patients and family caregivers with long-term self-management of COPD may increase acute care events compared to usual 30-day transitional care (JAMA 2019 Oct 8)

9 Oct 2019

eosinophil-guided corticosteroid therapy may be as effective as standard corticosteroid therapy for days alive and out of hospital within 14 days in patients aged ≥ 40 years hospitalized with acute exacerbation of COPD (Lancet Respir Med 2019 May)

9 Oct 2019

eosinophil-guided corticosteroid therapy may be as effective as standard corticosteroid therapy for days alive and out of hospital within 14 days in patients aged ≥ 40 years hospitalized with acute exacerbation of COPD (Lancet Respir Med 2019 May)

5 Sep 2019

targeted lung denervation may reduce COPD exacerbations needing hospitalization in patients with symptomatic moderate-to-severe COPD (Am J Respir Crit Care Med 2019 Aug)

5 Sep 2019

targeted lung denervation may reduce COPD exacerbations needing hospitalization in patients with symptomatic moderate-to-severe COPD (Am J Respir Crit Care Med 2019 Aug)

5 Sep 2019

insufficient evidence to evaluate efficacy and safety of head-to-head comparisons of prophylactic antibiotics in patients with COPD (Cochrane Database Syst Rev 2019 May)

5 Sep 2019

insufficient evidence to evaluate efficacy and safety of head-to-head comparisons of prophylactic antibiotics in patients with COPD (Cochrane Database Syst Rev 2019 May)

3 Sep 2019

fluticasone furoate/vilanterol may decrease moderate-to-severe exacerbations compared to umeclidinium/vilanterol in patients with blood eosinophil count ≥ 310 cells per mcL and in former smokers (Lancet Respir Med 2019 Jul 4 early online)

3 Sep 2019

fluticasone furoate/vilanterol may decrease moderate-to-severe exacerbations compared to umeclidinium/vilanterol in patients with blood eosinophil count ≥ 310 cells per mcL and in former smokers (Lancet Respir Med 2019 Jul 4 early online)

3 Sep 2019

magnitude of reduction in moderate-to-severe exacerbations with fluticasone furoate/umeclidinium/vilanterol compared to umeclidinium/vilanterol may be greater in patients with blood eosinophil count ≥ 310 cells per mcL and in former smokers (Lancet Respir Med 2019 Jul 4 early online)

3 Sep 2019

magnitude of reduction in moderate-to-severe exacerbations with fluticasone furoate/umeclidinium/vilanterol compared to umeclidinium/vilanterol may be greater in patients with blood eosinophil count ≥ 310 cells per mcL and in former smokers (Lancet Respir Med 2019 Jul 4 early online)

29 Aug 2019

oral mucolytics may reduce exacerbations, hospitalization, and days of disability in adults with chronic bronchitis or COPD (Cochrane Database Syst Rev 2019 May)

29 Aug 2019

oral mucolytics may reduce exacerbations, hospitalization, and days of disability in adults with chronic bronchitis or COPD (Cochrane Database Syst Rev 2019 May)

17 Jul 2019

addition of C-reactive protein (CRP) testing to usual care to guide prescription of antibiotics reduces antibiotic use without impairing health status in patients with acute exacerbation of COPD (N Engl J Med 2019 Jul 11)

17 Jul 2019

addition of C-reactive protein (CRP) testing to usual care to guide prescription of antibiotics reduces antibiotic use without impairing health status in patients with acute exacerbation of COPD (N Engl J Med 2019 Jul 11)

4 Jun 2019

benralizumab as adjunct to inhaled therapy does not reduce COPD exacerbations in patients with moderate to very severe COPD and elevated baseline eosinophil counts (N Engl J Med 2019 May 20 early online)

4 Jun 2019

benralizumab as adjunct to inhaled therapy does not reduce COPD exacerbations in patients with moderate to very severe COPD and elevated baseline eosinophil counts (N Engl J Med 2019 May 20 early online)

4 Jun 2019

low-dose azithromycin for 3 months might reduce treatment failure in adults hospitalized for acute exacerbation of COPD (Am J Respir Crit Care Med 2019 May 3 early online)

4 Jun 2019

low-dose azithromycin for 3 months might reduce treatment failure in adults hospitalized for acute exacerbation of COPD (Am J Respir Crit Care Med 2019 May 3 early online)

4 Jun 2019

prophylactic oral antibiotics may decrease exacerbations in adults with moderate or severe COPD without bronchiectasis (Cochrane Database Syst Rev 2018 Oct 30)

4 Jun 2019

prophylactic oral antibiotics may decrease exacerbations in adults with moderate or severe COPD without bronchiectasis (Cochrane Database Syst Rev 2018 Oct 30)

20 Mar 2019

Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy on diagnosis, management, and prevention of COPD (GOLD 2019)

20 Mar 2019

Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy on diagnosis, management, and prevention of COPD (GOLD 2019)

5 Mar 2019

daily aspirin use associated with reduced risk of moderate exacerbations and improved dyspnea in adults with COPD (Chest 2018 Dec 26 early online)

5 Mar 2019

daily aspirin use associated with reduced risk of moderate exacerbations and improved dyspnea in adults with COPD (Chest 2018 Dec 26 early online)

28 Nov 2018

triple therapy of LAMA plus ICS plus LABA may reduce risk of moderate-to-severe exacerbations in patients with advanced COPD (BMJ 2018 Nov 6)

28 Nov 2018

triple therapy of LAMA plus ICS plus LABA may reduce risk of moderate-to-severe exacerbations in patients with advanced COPD (BMJ 2018 Nov 6)

22 Jun 2018

beta blockers use does not appear to change improvements compared to no beta blockers at baseline in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment (Chest 2018 Jun)

22 Jun 2018

beta blockers use does not appear to change improvements compared to no beta blockers at baseline in patients with moderate to very severe COPD receiving long-acting bronchodilator treatment (Chest 2018 Jun)

top

Subscribe for unlimited access to DynaMed content.
Already subscribed? Sign in